Article ID Journal Published Year Pages File Type
3332052 Hematology/Oncology Clinics of North America 2008 14 Pages PDF
Abstract

Highly aggressive lymphomas are relatively uncommon in adults, comprising approximately 4% to 5% of all non-Hodgkin lymphomas in the United States and Western Europe. The designation of “highly aggressive” is generally restricted to precursor T-cell and B-cell lymphoblastic lymphoma/leukemia and Burkitt's lymphoma/leukemia. Treatment strategies for lymphoblastic lymphoma and Burkitt's lymphoma include complex, highly intensive combination chemotherapy regimens, which may be curative. As with other subtypes of NHL, emerging data from gene-expression profiling and related techniques are helping to define these entities more precisely and identify potential new rational therapeutic targets.

Related Topics
Health Sciences Medicine and Dentistry Hematology
Authors
,